Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,860 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Completed Phase 1Phase 2 Interventional

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

NCT01488552
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
Drug · Genetic
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

NCT04223609
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Placebo, EyeLink 1000 Plus, Oculo-Cognitive Addition test (OCAT), VT3mini - Eye Tracking Technology for OEMs
Drug · Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 59 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 20, 2026, 8:02 PM EDT
Active, not recruiting Phase 1 Interventional

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Newark, Delaware • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 1Phase 2 Interventional

Study of DF9001 in Patients With Advanced Solid Tumors

NCT05597839
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DF9001, KEYTRUDA® (pembrolizumab)
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 20, 2026, 8:02 PM EDT
Not listed No phase listed Observational

Testing Accountability in Patient Adherence

NCT01844557
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Swallowing Exercises, Symptom Inventory, Questionnaires
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 2 Interventional

Indirect Assessment and Intervention for Perinatal Drug Use

NCT01650675
View directory record Official record
Conditions
Drug Abuse
Interventions
WIDUS computer-delivered, indirect brief intervention, Nutrition time control/placebo intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Casinomacropeptide and Satiety

NCT01587911
View directory record Official record
Conditions
Lack of Satiety, Excess Intake of Macronutrients, Appetite Disorders
Interventions
Whey, Whey-CMP, Control, CMP, MPI, CPI
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CRT-Guanfacine for SPD

NCT02524899
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
Cognitive Remediation Therapy, Guanfacine, Placebo
Behavioral · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 1Phase 2 Interventional

Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study

NCT02262234
View directory record Official record
Conditions
Spinal Cord Injury, Chronic Pain
Interventions
Education Program Type 1, Education Program Type 2
Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

NCT05198232
View directory record Official record
Conditions
Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions
Zumba High Tempo, Zumba Low Tempo
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Classroom Behavior Support (CBS) Project

NCT05137327
View directory record Official record
Conditions
ADHD
Interventions
Classroom Behavior Support (CBS) Condition, Standard Problem Solving Consultation
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
5 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pasta Formulations, Portion Sizes and Their Effect on Appetite

NCT01199770
View directory record Official record
Conditions
Healthy, Appetite
Interventions
Control, small, Experimental B, small, Experimental pasta C, small, control, medium, experimental pasta B, medium, experimental pasta C, medium, NL
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Results available

Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments

NCT05723822
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Decline, Gait Disorders in Old Age
Interventions
Walkasins
Device
Lead sponsor
RxFunction Inc.
Industry
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

NCT03455829
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer
Interventions
G1T38, Osimertinib
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Flexibility as a Biomarker of Adaptation to Diet and Exercise Challenges

NCT01987388
View directory record Official record
Conditions
Healthy Volunteers
Interventions
High Intensity Exercise, Low Intensity Exercise, High Carbohydrate Beverage, High Fat Beverage
Other
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
22 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 20, 2026, 8:02 PM EDT
Recruiting No phase listed Observational

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

NCT05265429
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
Interventions
Data and Specimen Collection
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Active, not recruiting Not applicable Interventional

Osteopathic Manipulation Makes a Neuropsychological Difference

NCT04058431
View directory record Official record
Conditions
Cognitive Change, Musculoskeletal Pain
Interventions
Osteopathic Manipulative Treatment, Control- No Intervention
Other
Lead sponsor
Midwestern University
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 20, 2026, 8:02 PM EDT
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503
View directory record Official record
Conditions
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Interventions
LP-284
Drug
Lead sponsor
Lantern Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 1 Interventional

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

NCT03421353
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Results available

Trial Assessing Renal Damage During Ureteroscopy

NCT05350423
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Thulium Fibre Laser, Holmium:Yttrium-Aluminum-Garnet
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of Noninvasive Brain Stimulation in Parkinson's Disease

NCT01113086
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Transcranial direct current stimulation
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
40 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 20, 2026, 8:02 PM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
BNT326, Pumitamig
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 8:02 PM EDT